Article Submission Process Streamlined for Clinica Chimica Acta and Related Journals
|
By LabMedica International staff writers Posted on 26 Sep 2022 |

Submitting an article for a scientific publication is an essential step in the research process, but finding the right journal can be challenging. Often authors' first choice of journal turns out not to be the right one, requiring them to resubmit their article elsewhere, which can be a complex and time-consuming process.
Now, an initiative by Elsevier BV (Amsterdam, Netherlands), one of the world's largest scientific publishers with around 300 journals including Clinica Chimica Acta, recognizes this process isn’t always smooth, and aims to help authors find the best journal match for their article, quickly and easily.
To achieve this, a dedicated team of scientific editors use their subject-matter knowledge to analyze manuscripts, provide guidance and tailored recommendations for transfers to another Elsevier journal, working closely with editors from both originating and destination journals.
Authors who have received rejections, either before or after peer review, will be able to accept a transfer offer to a more suitable journal.
The program is designed to make the editorial process smoother and more efficient, so that transferred articles will flow through the Elsevier editorial submission system. This comes with the advantage that in many instances, authors won’t need to reformat the article but still have the option to make revisions if they want. Additionally, previous comments from editors and referees can be transmitted with the manuscript, ensuring all parties benefit from previous insights.
The most common types of transmissions are pre-review and post-review, where editors of the destination journal will make their own assessment based on the materials they receive. When the editor of the originating journal considers that an article is acceptable for publication in another journal, Elsevier's scientific managing editor can offer an enhanced offer to authors such as Recommended Acceptance, Guaranteed Peer-Review or Fast-Track Processing by the suggested journal.
For Recommended Acceptance, provided that authors address comments from the original editors/referees, and follow the instructions given in the transfer offer, publication in the alternative journal is expected without further peer review. Laura Guilherme Luzia, a scientific managing editor at Clinica Chimica Acta, added, "Elsevier's Article Transfer Service team understands that authors are unique, and that each article deserves to find its most suitable journal."
Related Links:
Elsevier BV
Clinica Chimica Acta
Elsevier Article Transfer Service
Latest Clinical Chem. News
- CE-Marked Blood Biomarker Test Advances Automated Alzheimer’s Diagnostics
- Noninvasive Urine Test May Support Earlier Diagnosis of Psychiatric Disorders
- At-Home Blood and Cognitive Tests Support Dementia Risk Stratification
- Ultrasensitive Test Detects Key Biomarker of Frontotemporal Dementia Subtype
- Routine Blood Tests Years Before Pregnancy Could Identify Preeclampsia Risk
- Blood Test Detects Testicular Cancer Missed by Standard Markers
- Routine Blood Tests Identify Biomarkers Linked to PTSD
- Proteomic Data Underscore Need for Age-Specific Pediatric Reference Ranges
- Routine Blood Count Ratio Linked to Future Alzheimer’s and Dementia Risk
- Label-Free Microfluidic Device Enriches Tumor Cells and Clusters from Pleural Effusions
- Rapid Biosensor Detects Pancreatic Cancer Biomarker for Early Detection
- Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation
- Blood Test Predicts Alzheimer Disease Risk Before Imaging Changes and Symptoms
- Study Finds ApoB Testing More Effective Than LDL for Guiding Lipid Therapy
- AI-Enabled POC Test Quantifies Multiple Cardiac Biomarkers
- Next Generation Automated Analyzers Increase Throughput for Clinical Chemistry and Electrolyte Testing
Channels
Molecular Diagnostics
view channel
Blood Test Refines Biopsy Decisions in Prostate Cancer
Prostate biopsy decisions remain challenging, with many men undergoing invasive procedures that ultimately yield negative results. In the U.S., more than a million prostate biopsies are performed each... Read more
Digital Aging Twin Quantifies Biological Aging Across Multiple Organ Systems
Chronological age often fails to capture the wide variability in physiological decline among adults, limiting risk stratification and long-term monitoring. Clinical laboratories also lack standardized... Read moreHematology
view channel
Stem Cell Biomarkers May Guide Precision Treatment in Acute Myeloid Leukemia
Acute myeloid leukemia (AML) is an aggressive blood cancer that most often affects older adults and still carries a poor prognosis despite therapeutic advances. Venetoclax-based regimens have improved... Read more
Advanced CBC-Derived Indices Integrated into Hematology Platforms
Diatron, a STRATEC brand, has introduced six advanced hematological indices on its Aquila, Aquarius 3, and Abacus 5 hematology analyzers. The new Research Use Only (RUO) indices include Neutrophil-to-Lymphocyte... Read moreImmunology
view channel
Biomarkers and Molecular Testing Advance Precision Allergy Care
Allergic diseases often present with similar symptoms but can be driven by distinct biological mechanisms, making standardized care inefficient for many patients. Historically, individuals with pollen... Read more
Point-of-Care Tests Could Expand Access to Mpox Diagnosis
Mpox outbreaks in non-endemic regions have underscored the need for rapid, accessible diagnostics to limit transmission. Polymerase chain reaction (PCR) remains the clinical reference, yet it depends on... Read moreMicrobiology
view channel
Molecular Urine and Stool Tests Do Not Improve Early TB Treatment in Hospitalized HIV Patients
Tuberculosis is the leading cause of death among people living with HIV, and diagnosis in hospital settings remains difficult. Symptoms are often non-specific, disease can be extrapulmonary, and many patients... Read more
Rapid Antigen Biosensor Detects Active Tuberculosis in One Hour
Tuberculosis remains a major global health challenge and continues to drive significant morbidity and mortality. The World Health Organization’s 2024 global report cites it as the leading cause of death... Read morePathology
view channel
FDA Clears AI Digital Pathology Tool for Breast Cancer Risk Stratification
Risk assessment at diagnosis is central to guiding therapy for early-stage, hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) invasive breast cancer, where overtreatment... Read more
New AI Tool Reveals Hidden Genetic Signals in Routine H&E Slides
Pathologists worldwide rely on hematoxylin and eosin (H&E) slides to examine tissue architecture, yet these stains do not reveal the underlying molecular activity that often drives disease.... Read moreTechnology
view channel
Fully Automated Sample-to-Insight Workflow Advances Latent TB Testing
Latent tuberculosis remains a substantial testing workload for clinical laboratories as screening programs expand. Despite this growth, only about 40% of testing has shifted from traditional skin tests... Read more
Tumor-on-a-Chip Platform Models Pancreatic Cancer Treatment Response
Pancreatic cancer remains one of the hardest malignancies to treat because tumors are embedded within a dense microenvironment that shapes growth and therapy response. Standard laboratory models often... Read moreIndustry
view channel
Roche to Acquire PathAI for Up to $1.05 Billion to Strengthen AI Diagnostics Portfolio
Roche has entered into a definitive merger agreement to acquire PathAI, a company focused on digital pathology and artificial intelligence for pathology laboratories and the biopharma industry.... Read more




.jpg)



